by Katie Honeywood | Mar 21, 2025 | Clinical Trials, Research
Treatment for progressing bone sarcomas can be challenging. This is especially true after patients have had drugs to treat cancer but the cancer is still progressing. A potential combination therapy of immunotherapy and TKI inhibitor treatment could help improve...
by Katie Honeywood | Feb 7, 2025 | Clinical Trials, Research
Osteosarcoma (OS) is the most common bone cancer in children and young adults. It is more common in those aged 10 to 19 years. It affects about 3.4 people per million each year worldwide. This cancer comes back in 30% to 40% patients with localized disease. It...
by Katie Honeywood | Nov 18, 2024 | Clinical Trials, Research
miRNAs – what are they? Ribonucleic acid is also known as RNA. It is a cell building block that is in all living cells and has structural similarities to DNA. Three different types of RNA exist in cells: Messenger RNA (mRNA), Ribosomal RNA (rRNA) Transfer RNA (tRNA)....
by Katie Honeywood | Sep 20, 2024 | Clinical Trials, Research
Patients with osteosarcoma (OS) which has spread to the lungs (lung metastasised osteosaroma, or LMOS) have poor survival rates. Nomograms are a form of predictive technology used in medicine. They are particularl3 This randomized control trial looked at risk factors...
by Katie Honeywood | Sep 4, 2024 | Clinical Trials, Research
The trial in this blog was originally undertaken in the mid-1990s. The trial followed up the patients who received the treatment after the trial for 25 years. This paper follows up the participants from the original trial and is one of the longest follow up...
by Katie Honeywood | Jul 25, 2024 | Clinical Trials, Research
What is this trial about? It is well known that osteosarcoma (OS) treatments have had limited success in helping patients with the disease. Previous research shows you can ’arm’ T-cells with a special molecule called GD2-specific antibody. GD2 is protein found in...
